Teva Pharmaceutical Industries (NYSE:TEVA) EVP Richard Daniell Sells 30,000 Shares of Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the sale, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. This trade represents a 34.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Richard Daniell also recently made the following trade(s):

• On Thursday, March 5th, Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $31.67, for a total value of $547,732.65.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $36.00 on Friday. The company has a market cap of $41.39 billion, a PE ratio of 27.07, a price-to-earnings-growth ratio of 3.51 and a beta of 0.86. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The stock has a 50-day moving average price of $31.28 and a 200-day moving average price of $29.81. Teva Pharmaceutical Industries Ltd. has a 12-month low of $14.99 and a 12-month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.49 earnings per share for the current fiscal year.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds have recently bought and sold shares of TEVA. Aster Capital Management DIFC Ltd bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $25,000. Cornerstone Planning Group LLC lifted its position in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after purchasing an additional 755 shares during the last quarter. Allworth Financial LP lifted its position in Teva Pharmaceutical Industries by 53.8% in the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares during the last quarter. Grove Bank & Trust lifted its position in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Scotiabank boosted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Barclays boosted their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday. Truist Financial boosted their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, Bank of America boosted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $41.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.